Automation-Ready Reagents Used with the
Hamilton Robotics Liquid-Handler Streamlines and Helps Accelerate
Lab Work Leading to Genomic Sequencing
FRANKLIN
LAKES, N.J., Oct. 14,
2024 /PRNewswire/ -- BD (Becton, Dickinson and
Company) (NYSE: BDX), a leading global medical technology company,
today announced the commercial launch of the first in a family of
high-throughput, robotics-compatible reagent kits that will enable
automation to ensure greater consistency and increased efficiency
of large-scale, single-cell discovery studies.
The automated solution from the BD and Hamilton collaboration
standardizes traditionally manual processes and speeds the
generation of material for genetic sequencing. The solution
includes the newly released BD® OMICS-One XT WTA Assay
and the Hamilton® Microlab™ NGS STAR automated liquid handling
platform. Because the NGS STAR is already installed in many
laboratories and facilities worldwide, more researchers, processing
samples across an array of genomics applications, can easily
integrate the new automation-ready BD® assay into
existing workflows.
In single-cell discovery studies involving genetic material,
constructing preparatory material otherwise called "DNA libraries"
is an essential early step. Historically, such preparations have
been labor-intensive and time-consuming processes, with numerous
manual steps that often lead to variability of results, compromised
data quality, limited throughput, high cost and long turnaround
times.
"By automating the complex library preparation process,
researchers can scale their sample throughput and expect more
consistent results, minimizing the variability introduced by manual
procedures," said Steve Conly,
worldwide president of BD Biosciences. "This standardization is
crucial for the reproducibility of experiments, which is a
cornerstone of scientific research. The integration of Hamilton's
robotics with BD's robotics-ready reagent kits can streamline
workflows, reduce the potential for human error, and accelerate the
pace of discovery in critical areas such as oncology and
immunology."
Matt Hamilton, CEO at Hamilton
added, "Hamilton's advanced automated solutions streamline
scientific workflows, maximizing the potential of single-cell
multiomics research. Our partnership with BD furthers our mission
to provide innovative technologies that accelerate groundbreaking
discoveries in science and medicine."
The BD® OMICS-One XT Library Preparation Reagent Kits
and Hamilton Microlab NGS STAR automated liquid handling platform
and applications are commercially available globally. The robotics
liquid-handling platform is available for purchase from Hamilton,
and the reagent kits are available for purchase from BD
representatives, or in some regions, through BD's e-commerce
portal. More information is available at bdbiosciences.com or
through BD sales representatives.
About BD
BD is one of the largest global medical
technology companies in the world and is advancing the world of
health by improving medical discovery, diagnostics and the delivery
of care. The company supports the heroes on the frontlines of
health care by developing innovative technology, services and
solutions that help advance both clinical therapy for patients and
clinical process for health care providers. BD and its more than
70,000 employees have a passion and commitment to help enhance the
safety and efficiency of clinicians' care delivery process, enable
laboratory scientists to accurately detect disease and advance
researchers' capabilities to develop the next generation of
diagnostics and therapeutics. BD has a presence in virtually every
country and partners with organizations around the world to address
some of the most challenging global health issues. By working in
close collaboration with customers, BD can help enhance outcomes,
lower costs, increase efficiencies, improve safety and expand
access to health care. For more information on BD, please visit
bd.com or connect with us on LinkedIn at
www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or
Instagram @becton_dickinson.
Contacts:
Media:
Investors:
Troy Kirkpatrick
Adam Reiffe
VP, Public Relations
Sr. Director, Investor Relations
858.617.2361
201.847.6927
troy.kirkpatrick@bd.com
adam.reiffe@bd.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bd-announces-new-robotics-solution-to-automate-standardize-single-cell-research-302274570.html
SOURCE BD (Becton, Dickinson and Company)
